ACTC to Present Sept 10th

MARLBOROUGH, Mass., Sep 07, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that ACT's chairman and CEO Gary Rabin will be presenting at the 14th Annual Rodman & Renshaw Global Investment Conference, Sept. 9-11 in New York. Mr. Rabin's presentation will take place on Monday, Sept. 10, at 12:05 p.m. EDT, at the Waldorf Astoria.
The presentation will be webcast live (link here) and the presentation slide deck will be available on the conference presentations section of the ACT website.
Should move share price up.

Good luck in this rigged casino,

Geron New 52 Week High

Geron closed up at $2.845 the new 52 week high is $2.88 on over 2 million shares. The three month avg. is 967,411 shares. Volume has been good and we keep going up. $3.00+  Next stop. If we keep going up on good volume I would say the Phase two trials are going to have good results and it's known by a few people who are buying.

ACTC closed down just a little 0.8018 on 2.5 million shares. The three month avg. volume is 4.8 million shares.

AAPL closed up at $676.27 on 14 million shares. The three month avg. volume is 13.6 million shares.

Good luck in this rigged casino,

Geron's CEO Chip was good

Geron's CEO "Chip" give a good presentation at the Stifiel Nicolaus Healthcare Conference. You can listen to and watch at there website. Geron closed down at $2.73 on 1.7 million shares. We also hit a new 52 week high of $2.83.  The three month  avg. volume is 933,738 shares. What I think from listening to "Chip" is the Breast Cancer phase two trial are going well [having good results the patients are living longer] because they where going to report results at the end of Dec 2012 and had to move it to 1st Q of 2013.  I think we will still go a little lower before Dec 2012. If it all works out in Geron's favor we will hit $5 by 2013. If not we will be under $2.

Good luck in this rigged casino,

Geron new 52 week high

Geron closed at $2.79 up three cents and hit a new 52 week high of $2.82. The volume was 1.6 million shares. The three month avg. volume is 908,797.  Geron's CEO "Chip" will speak Sept 5th Wed at 10:55 AM.  Hoping for something new.

AAPL up to close at $674.97 on 13 million shares. The three month avg. volume is 13.6 million shares.

ACTC closed up a little at 0.0829 on 3.9 million shares. The three month avg. 4.8 million shares.

Good luck in this rigged casino,

Seeking Alpha on Geron today

Geron (GERN) - Imetelstat: Following its consolidation in the oncology field, Geron is currently conducting four Phase II studies with Imetelstat, a first-in-class telomerase inhibitor targeted at solid tumors and hematological malignancies. One of Imetelstat's main advantages, which is derived from its mode of action, is that it could be suitable for treating a wide varaiety of tumors. Should results from the Phase II studies, expected during 2013, will prove efficacy this drug will become a strong candidate for a licensing deal.
The Phase two trials have to be good or Geron is done.

Good luck in this rigged casino,

ACTC Dr. Lanza to Deliver Opening Speech 4th Annual

ACT's Chief Scientific Officer Dr. Robert Lanza to Deliver Opening Keynote Address at 4th Annual Stem Cell Symposium in Singapore

Sep 4, 2012 08:30:02 (ET)

MARLBOROUGH, Mass., Sep 04, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering the opening Keynote Speech at the 4th Annual Stem Cell Symposium 2012, being held in Singapore, September 6-7. Dr. Lanza's presentation is titled "Pluripotent Stem Cells -- From Benchtop to Clinic."
With the theme, "Stem Cell Based Therapy," the symposium will have a particular focus on clinical trials and industrial application of stem cells. Sponsored by Stem Cell Society of Singapore (SCSS), the conference will include scientific presentations from key contributors from academic, clinical, and commercial organizations who are translating basic research on stem cells into therapeutics, with a focus on applying engineering technologies to provide medical solutions.
In their opening statement, the organizers state, "We are all keeping our 'fingers crossed' for ACT's success, which will also bring a big boost to the stem cell community."
Other topics of the conference include human induced pluripotent stem cells (hiPSCs), drug screening, adult and cancer stem cells, and stem cell therapies emerging from Asia, with presentations from Indian, Korean and Japanese regenerative medicine companies. There will also be a joint session with the International Society for Cellular Therapy (ISCT) covering important issues concerning the commercialization of stem cells, and addressing issues such as reimbursement, manufacturing, characterization, and clinical implementation issues unique to cell therapies.

Geron's CEO "Chip" will speak Wed at 10:55AM it will be webcast, should move the share price up or down. Geron has had a great run from $1.71 on Aug 17th to $2.76 today.

Good luck in this rigged casino,

Geron good run, but to soon

Biotech Geron (Nasdaq: GERN ) was perhaps the one stock rising for a reason, as an analyst offered a positive outlook on the cancer therapies it's developing, but the stock has been on the move for awhile now (up 60% over the past month) after a positive review two weeks ago on Seeking Alpha. I said at the time the treatments hold a lot of promise, but the results of midstage trials have some time to go before we see the actual outcome, so the spike in its shares now seems a bit premature. I'd say the same for the current run-up based on the rosy view offered up by the Wall Street analyst.

Good luck in this rigged casino,